SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/forms-1.htm

Chunk 31 of 83
Word Count: 1472
Character Count: 9308

Document Content:

of expenses in differing jurisdictions. Our future effective tax rates could be subject to volatility or adversely affected by a number of factors, including: ● changes in the valuation of our deferred tax assets and liabilities; ● expected timing and amount of the release of any tax valuation allowances; ● tax effects of stock-based compensation; ● costs related to intercompany restructurings; or ● changes in tax laws, regulations or interpretations thereof. addition, we may be subject to audits of our income, sales and other transaction taxes by federal, state and local authorities. Outcomes from these audits could have an adverse effect on our financial condition and results of operations. Provisions in our charter documents and under Delaware law, including anti-takeover provisions, could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may limit attempts by our stockholders to replace or remove our current management.

Our
fourth amended and restated certificate of incorporation and amended and restated bylaws to be in effect following the consummation of
this offering (the “Amended and Restated COI” and the “Amended and Restated Bylaws,” respectively) include anti-takeover
provisions, which may have the effect of delaying or preventing a merger, acquisition or other change of control of us that our stockholders
may consider favorable. In addition, because our board of directors is responsible for appointing the members of our management team,
these provisions may frustrate or prevent any attempts by our stockholders to replace or remove current management by making it more
difficult for stockholders to replace members of our board of directors. Among other things, the charter and bylaws include provisions
that:

●	require
super-majority voting to amend the bylaws and certain provisions in the charter;

●	provide
that only a majority of our board of directors, the chairman of our board of directors, our co-chief executive officers, our Vice
Chairman (if any), our President or stockholders collectively holding more than 50% of our voting securities will be authorized to
call a special meeting of stockholders;

not provide for cumulative voting;

●	prohibit
stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;

●	provide
that our board of directors is expressly authorized to make, alter, or repeal our bylaws, subject to DGCL requirements; and

●	establish
advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon
by stockholders at annual stockholder meetings.

Public
stockholders who might desire to participate in these types of transactions may not have an opportunity to do so, even if the transaction
is considered favorable to stockholders. These anti-takeover provisions could substantially impede the ability of public stockholders
to benefit from a change in control or a change in our management and board of directors and, as a result, may adversely affect the market
price of our common stock and your ability to realize any potential change of control premium.

have never paid dividends on our capital stock, and we do not anticipate paying dividends for the foreseeable future.

have never declared or paid any cash dividends on our capital stock, and we do not anticipate paying any cash dividends in the foreseeable
future. The payment of dividends, if any, in the future is within the discretion of our board of directors and will depend on our earnings,
capital requirements and financial condition and other relevant facts. We currently intend to retain all future earnings, if any, to
finance the development and growth of our business. Accordingly, you must rely on the sale of your common stock after price appreciation,
which may never occur, as the only way to realize any future gain on your investment.

Our
Amended and Restated COI designates certain courts as the sole and exclusive forum for certain types of actions and proceedings that
may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes
with us or our directors, officers, or employees.

Our
Amended and Restated COI provides that, unless we consent in writing to the selection of an alternative forum, a state or federal court
located in the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf
of us, (ii) any action asserting a claim for breach of a fiduciary duty owed by any director, officer or other employee of the
Company to the Company or the Company’s stockholders, (iii) any actions asserting a claim arising pursuant to any provision of
the DGCL, the certificate of incorporation or the bylaws of the Company, in each case as amended, or (iv) any action asserting a claim
governed by the internal affairs doctrine, in each such case subject to such court having personal jurisdiction over the indispensable
parties named as defendants therein (the “Delaware Forum Provision”). This, however, shall not apply to claims or causes
of action brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for which the
federal courts have exclusive jurisdiction. Our bylaws further provide that, unless we consent in writing to the selection of an alternative
forum, the federal district courts of the United States of America shall be the sole and exclusive forum for resolving any complaint
asserting a cause of action arising under the Securities Act (the “Federal Forum Provision”). In addition, our bylaws provide
that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and
consented to the Delaware Forum Provision and the Federal Forum Provision.

Section
27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the
Exchange Act or the rules and regulations thereunder. As a result, the Delaware Forum Provision will not apply to suits brought to enforce
any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. We note,
however, that there is uncertainty as to whether a court would enforce this provision and that investors cannot waive compliance with
the federal securities laws and the rules and regulations thereunder.

recognize that the Delaware Forum Provision and the Federal Forum Provision in our bylaws may impose additional litigation costs on stockholders
in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware. Additionally, the Delaware
Forum Provision and the Federal Forum Provision may limit our stockholders’ ability to bring a claim in a forum that they find
favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors,
officers and employees even though an action, if successful, might benefit our stockholders. If the Federal Forum Provision is found
to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose
additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The competent courts of the
State of Delaware and the United States District Court may also reach different judgments or results than would other courts, including
courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may
be more or less favorable to us than our stockholders.

Our
ability to use our U.S. net operating loss carryforwards to offset future taxable income may be subject to certain limitations.

of December 31, 2025, we had U.S. federal net operating loss (“NOL”) carryforwards of approximately $183.8
million, which may be available to offset federal income tax liabilities in the future. In addition, we may generate additional NOLs
in future years. In general, a corporation’s ability to utilize its NOLs may be limited if it experiences an “ownership change”
as defined in Section 382 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). An ownership change generally
occurs if certain direct or indirect “5- percent shareholders,” as defined in Section 382 of the Code, increase their aggregate
percentage ownership of a corporation’s stock by more than 50 percentage points over their lowest percentage ownership at any time
during the testing period, which is generally the three-year period preceding any potential ownership change. If a corporation experiences
an ownership change, the corporation will be subject to an annual limitation that applies to the amount of pre-ownership change NOLs
that may be used to offset post-ownership change.

qualify as an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements
applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors.